Texas-based Asuragen, Inc. announced today that it has received over $3.8 million in new grant funding for 2009 from the Small Business Innovative Research (SBIR), Small Business Technology Transfer (STTR), and American Recovery and Reinvestment Act (ARRA) funded initiatives of the National Institutes of Health (NIH) to further its development of molecular diagnostics for oncology and genetic disease.Since the Company was spun off from Ambion in 2006, Asuragen has received more than 20 NIH small business grants totaling approximately $12 million, mostly in the area of oncology diagnostics, miRNA, and innovative technologies to facilitate molecular diagnostic development and discovery.
For more details, visit:
www.reuters.com/article/pressRelease/idUS151970+07-Oct-2009+BW20091007
